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Amphiphilic block copolymers have been developed for the encapsulation of organometallic drugs. silver–N-
heterocyclic carbene complexes have shown signiﬁcant promise as anticancer and antibacterial compounds,
and have been studied as the payload in these carriers. Simple modiﬁcation of the N-heterocyclic carbene
ligand structure enables solubility properties and interaction with the polymer to be tuned.Introduction
Silver has long been established as having antibacterial prop-
erties,1 and more recently the chemotherapeutic eﬀects of silver
have been recognised.2,3 Silver salts, nanoparticles and
compounds such as silver sulfadiazine have been used in
healthcare. Recently, silver–N-heterocyclic carbene (NHC)
complexes have shown signicant promise as potential anti-
bacterial and anticancer drugs,4–9 and are thought to have
a relatively slow silver release rate which is ideal for prolonged
activity. The in vitro eﬀects of silver–NHCs, however, do not
usually translate into comparable in vivo activity, due to lack of
targeting and change in metal speciation upon entering a bio-
logical environment.10 It is therefore desirable to develop
delivery systems which act to protect the drug, target the site of
action and release the drug in response to specic stimuli.
Polymer-based drug delivery systems have demonstrated
extensive promise for the controlled release of organic thera-
peutics at a target site in vivo.11 The polymer acts to prevent the
premature metabolism of the drug prior to its intended deploy-
ment,12 and also protects healthy cells from exposure to what are
oen cytotoxic drug molecules.13 Enhanced drug concentrations
are consequently found at the diseased cells, enabling lower
concentrations to be administered and ensuring that the side-
eﬀects that are associated with treatments, such as chemo-
therapy, are restricted.14 Although extensive research has been
undertaken to develop polymeric systems for the controlled
delivery of organic drugs, the controlled release of organome-
tallic payloads as drug delivery systems is relatively under-
developed.15 Cisplatin has been incorporated into polymeric
micelles,16–18 and Youngs and co-workers have reported drug-Woodhouse Lane, Leeds, LS2 9JT, UK.
derseld, Queensgate, Hudderseld, HD1
tion (ESI) available. See DOI:
7delivery vehicles for silver–NHC complexes, in the form of
polymer-based nanoparticles,19 with the expansion of this highly-
promising research domain being of great medicinal value.
Herein, we report organometallic drug encapsulation within
biodegradable polymeric nanoparticles, and an assessment of
the cytotoxic prole of the nanoparticles produced. Signicantly,
a novel loading approach in which the silver–NHC complex
mediates transformation of water-soluble polymers into silver-
containing nanoparticles is described and demonstrated. This
is possible as many of the polymers used in this study contain
functional groups capable of ionic crosslinking to yield nano-
particles. Such functional groups also permit nanoparticle
modication with cell-binding groups, an essential feature for
the future development of targeted drug delivery systems.Results and discussion
Silver–NHC complexes used in this study (Fig. 1) were chosen
based upon their aqueous solubility (C1, C2), uorescentFig. 1 Cytotoxic silver–NHC complexes studied for encapsulation
within polymeric nanoparticles.
This journal is © The Royal Society of Chemistry 2018
Fig. 3 (a) SEM image of silver–NHC C1 loaded P1 particles. (b) EDX
map corresponding to an area that is located within a loaded particle.
(c) EDX spectrum corresponding to an area that is located within the
loaded particle, showing the presence of silver. Other elements that
appear on the spectrum emanated from the composition of the SEM
glass cover slide and from the gold-coating.
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View Article Onlineproperties (C2, C3), and the ability to form electrostatic inter-
actions with cationic polymers, through interaction with
anionic carboxylate groups (C3, C4).
Initially, methoxy-poly(ethylene glycol)-b-poly(phenylalanine)
(P1) (synthesised as mPEG113-b-poly(Phe)24) was used to deter-
mine the feasibility of encapsulating organometallic
compounds within poly(amino acid)-containing polymers. P1 is
an amphiphilic co-polymer that can self-assemble in aqueous
media (Fig. 2), and due to the phenylalanine content is suscep-
tible to hydrolysis by chymotrypsin, a digestive enzyme that is
secreted by the pancreas.12 Self-assembly of P1 was demon-
strated through its addition to water (10 mg mL1). Scanning
electron microscopy (SEM) conrmed the production of nano-
particles (Fig. 2a) that possessed an average size of 121 nm, as
determined by dynamic light scattering (DLS) (Fig. 2b).
Encapsulation of a silver–NHC by P1 was investigated using
the water-soluble complex C1, with varying ratios of P1 : C1
(ESI†). DLS analysis revealed an increased average particle size
of 151.7 nm and PDI of 0.307 when using 0.8 : 1 ratio of P1 : C1.
SEM analysis of P1 : C1 revealed the formation of discrete
particles (Fig. 3a), with energy-dispersive X-ray spectroscopy
(EDX) mapping the location of silver ions. SEM-EDX reveals that
the silver ions are located within the particle region, indicating
successful encapsulation of silver–NHC C1 (Fig. 3b). The EDX
spectrum shows peaks corresponding to silver and chloride
ions, supporting the presence of the complex within the particle
region (Fig. 3c).
To emphasise further the encapsulation of silver–NHCs in P1
particles, the intrinsic uorescence property of complex C2
(Fig. 1) was exploited to map the location of the complex in the
particles. Confocal laser scanning microscopy was used to
image the C2-loaded particles. Imaging was carried out under
visible light to map the polymeric shell (Fig. 4a) and under
uorescence to map the inherently uorescent silver–NHC
complex (Fig. 4b). These images were overlaid (Fig. 4c) and
resolved further to reveal clearly the two distinct regions in theFig. 2 The envisaged self-aggregation of P1 into particles that can
physically entrap silver(I)–NHC complexes (top). (a) SEM micropho-
tograph showing the formation of nanoparticles, scale bar represents 1
mm. (b) DLS data revealing the size distribution of particles.
Fig. 4 Confocal microscopy images obtained from C2-loaded
mPEG5000-b-poly(Phe)24 particles: (a) under visible light, (b) under
ﬂuorescence, (c) an overlay of the two images, (d) highly resolved
image revealing that the blue ﬂuorescent spots (i.e. assumed to be the
molecules of the encapsulated complexes) occupy the same positions
as the black clusters (which are assumed to be the polymeric shell).
Scale bars represent 1 mm.
This journal is © The Royal Society of Chemistry 2018particles (Fig. 4d). The discrete clusters that uoresced, and
were thus assumed to be the silver–NHC complex, occupy
positions that coincide with the positions of the dark spots
(assumed to be the discrete polymeric particles) (Fig. 4c and d).
As such, it can be summarised that the silver–NHC complexesRSC Adv., 2018, 8, 10474–10477 | 10475
Table 1 Polydispersity index (PDI) and average particle size (APS) for
conjugated PNs
Polymer Imidazolium or silver–NHC PDI APS (nm)
P2 L3 1.000 146.0
P3 L3 0.754 173.1
P4 L3 0.292 224.2
P2 C3 0.188 159.7
P3 C3 0.173 175.6
P4 C3 0.153 176.5
P2 L4 1.000 121.8
P3 L4 a a
P4 L4 0.484 253.2
P2 C4 0.249 160.8
P3 C4 0.173 452.7
P4 C4 0.449 221.8
a A reading could not obtained.
Fig. 6 SEM images of P3 : C4. Scale bar represents (a) 5 mM, and (b)
1 mM.
Table 2 Response of Panc 10.05 and ARPE-19 cells to silver–NHC
RSC Advances Paper
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View Article Onlineeither become adsorbed onto the polymeric particles or are
encapsulated within the polymer during nanoparticle assembly.
The latter possibility is more plausible because of the intrinsic
hydrophobicity of the metal complex.
The use of organometallic-polymer conjugation to instigate
nanoparticle formation was investigated using NHCs with
carboxylic acid N-substituents (C3 and C4) and amine-
presenting polymers, with the aim of forming electrostatic
interactions between the deprotonated anionic carboxylate
groups and the cationic polymer. Poly(L-lysine) may be
employed as a biodegradable, cationic polymer capable of
binding with anionic carboxylate groups, hence methoxy-
poly(ethylene glycol)-b-poly(L-lysine) was used in this study
(Fig. 5). This method of encapsulation ensures that nano-
particles are only formed from the water-soluble polymers when
contact between the drug and the poly(L-lysine) component of
the block copolymer occurs, thereby eliminating the possibility
of conjugation of the drug to the surface of pre-formed PNs.
Polymers with varying mPEG:poly(L-lysine) ratios (P2, P3 and
P4), were prepared using PEG as the macroinitiator for the ring-
opening polymerisation of L-lysine N-carboxyanhydrides
(ESI†).20
Solutions of the three polymers P2, P3 and P4, and solutions
of silver–NHC complexes C3 and C4were prepared (1 mgmL1).
In addition to complexes C3 and C4, the corresponding imi-
dazolium ligand precursors L3 and L4 were also examined. All
solutions were initially ltered through PTFE syringes with pore
size of 0.45 mm followed by ltration using a lter with a pore
size of 0.2 mm to remove all particles that possess a diameter
greater than 0.2 mm, as conrmed by DLS analysis. Filtered
solutions of each polymer and either silver–NHC complex C3 or
C4, or imidazolium L3 or L4, were combined (1 : 1) at 37 C and
analysed using DLS (Table 1). DLS conrmed the absence of
particles in the individual polymer, metal complex and imida-
zolium solutions, by revealing blank DLS charts. When the
respective polymer solutions were mixed with silver–NHC
complex solutions (1 : 1 v/v), DLS conrmed the formation of
particles, by revealing the emergence of size distribution traces
that were initially not present in either the independent poly-
mer solutions or in the complex solutions. The particle diam-
eters generally increased with increasing polymer length, as
expected. However, in the case of P3 : C4, a larger than expected
particle diameter of 452.7 nm was observed which suggests
vesicle formation (Fig. 6). Both imidazolium salts and corre-
sponding silver–NHC complexes form particles of similar size,Fig. 5 Methoxy-poly(ethylene glycol)-b-poly(L-lysine). P2: n ¼ 113,m
¼ 39. P3: n ¼ 113, m ¼ 50. P4: n ¼ 113, m ¼ 140.
10476 | RSC Adv., 2018, 8, 10474–10477indicating that the ligand plays the major role in particle
formation, which is not aﬀected by the presence of silver.
Encapsulation of a drug carries the risk of impeding cyto-
toxic behaviour. To assess the viability of encapsulated silver–
NHCs against cancer cells, activities of P1 : C1, P3 : C3 and
P3 : C4 were evaluated against the pancreatic adenocarcinoma
cell line Panc 10.05 using MTT-based assays. Silver–NHC
complexes C1, C3 and C4 were also tested as comparators
(Table 2). There is clear evidence from the results presented in
Table 2 that encapsulation of silver–NHCs by the polymers
investigated in this study does not adversely aﬀect the cytotox-
icity of the complexes to Panc 10.03 cancer cells. Selectivity of
C1 and C3 does decrease upon encapsulation when the IC50complexes C1, C3 and C4, and polymeric nanoparticles PN2, PN3B
and PN4B. Values presented are IC50 mM  SD for three independent
experiments. The selectivity index is deﬁned as the ratio of IC50 in non-
cancer ARPE-19 cells to the IC50 in cancer Panc 10.05 cells
Drug Panc 10.05 ARPE-19
Selectivity
index
C1 30.57  13.16 >100 >3.27
P1 : C1 25.8  4.3 22.70  2.70 1.43
C3 12.3  3.2 >100 >8.15
P3 : C3 8.2  1.8 23.59  6.88 2.86
C4 26.3  11.5 68.70  7.16 2.61
P3 : C4 16.0  5.5 83.37  17.06 3.23
This journal is © The Royal Society of Chemistry 2018
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View Article Onlinevalues against non-cancer ARPE-19 cells are compared to IC50
values for Panc 10.03, though the selectivity of C4 improves
upon encapsulation. These results present signicant promise,
as encapsulation may feasibly prevent decomposition of the
drug before it reaches the intended target site, and may enable
an enhanced, and thus more eﬀective concentration of inor-
ganic therapeutic to be delivered to the target site.Conclusions
In conclusion, we have presented novel methods towards organ-
ometallic drug delivery systems involving encapsulation within
polymeric nanoparticles. The polymers used in this study oﬀer
the potential for structural modication, enabling targeted
carriers to be developed. The structural diversity of NHC ligands
allows the interaction between the polymer and drug to be
altered, thus changing the physical properties of the nano-
particles. Importantly, the silver–NHCs studied in this work retain
their cytotoxic prole against cancerous Panc 10.05 cells upon
encapsulation within the polymers, making these systems viable
for organometallic drug delivery. Work is ongoing to understand
the drug loading eﬃciencies and pharmacokinetic behaviour of
the drug-loaded nanoparticles, which will enable optimisation of
these systems through ligand and/or polymer modication.Conﬂicts of interest
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